Recent News

• 01.05.2026 - Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
• 12.05.2025 - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 11.25.2025 - UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
• 11.06.2025 - UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
• 11.04.2025 - UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

Recent Filings

• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.19.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors